Changes in Hong Kong stocks | Xinwei Medical-B (06609) rose more than 5% in the first half of the year, ischemic stroke business revenue continued to increase steadily, and the company steadily advanced the A-share IPO process

The Zhitong Finance App learned that Xinwei Medical-B (06609) rose by more than 5%. As of press release, it had risen 4.86% to HK$52.2, with a turnover of HK$2.374,900.

According to the news, recently, Xinwei Medical announced the 2026 interim results announcement. In the first half of 2026, the company achieved revenue of 290 million yuan, an increase of 56.9% year on year; net profit of 63.65 million yuan, up 18.5% year on year; adjusted net profit of about 73.67 million yuan, an increase of 105.9% year on year. In the first half of 2026, the company's ischemic stroke business revenue continued to grow steadily. The key product intracranial thrombus suction catheter was added to about 200 new hospitals, and the number of products implanted increased more than 3 times over the same period last year.

It is worth noting that in the second half of 2026, Xinwei Medical plans to submit an application for the initial public offering of A shares to the Shanghai Stock Exchange and listing on the Science and Technology Innovation Board. It is estimated to raise about 500 million yuan in capital, with an estimated issuance ratio of about 15%, and will continue to promote stock repurchases and cash dividends in accordance with the company's business conditions and regulatory requirements. CITIC Construction Investment said that the company is steadily advancing the A-share IPO process and is expected to further enhance capital market liquidity and accelerate the company's commercialization in the global market through the A-share IPO listing in the future.